免疫相关不良事件是HCC移植后排斥反应的强预测因素
这项多中心回顾性研究纳入209例2018至2024年移植前接受免疫检查点抑制剂的成人肝细胞癌患者,17.2%发生移植后排斥,中位时间10天。多因素分析显示免疫相关不良事件是最强预测因素(OR=9.170,p<0.001),预测模型AUC为0.788。
要点
- 移植前使用ICI的HCC患者中,irAEs是移植后排斥的最强预测因素(OR=9.170)。
- 受者年龄<40岁和洗脱期<30天也是排斥的独立危险因素。
- 预测模型AUC为0.788,可用于分层排斥高风险患者。
核心结论
- irAEs是HCC患者移植前接受ICI后发生移植物排斥的强预测因素,可能由免疫激活增强驱动。
研究设计与样本
- 全国多中心回顾性队列研究,纳入209例2018至2024年接受移植前ICI的成人HCC患者。
- 另纳入23例HCC患者的前瞻性观察队列,探索外周血免疫表型与irAEs的关联。
主要发现
- 209例中36例(17.2%)发生排斥,中位时间为移植后10天。
- 多因素分析显示irAEs是最强排斥预测因素,OR为9.170(p<0.001)。
- 其他独立危险因素包括受者年龄<40岁(OR=3.028,p=0.049)和洗脱期<30天(OR=3.071,p=0.018)。
- 预测模型AUC为0.788。
- 有irAEs者外周血CD8+ T细胞数量及IFN-α、TNF-α水平显著高于无irAEs者(均p<0.05)。
临床怎么用
- 移植前接受ICI的HCC患者应评估irAEs以分层移植后排斥风险。
- 预测模型可辅助识别排斥高风险患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Immune checkpoint inhibitors (ICIs) enable successful hepatocellular carcinoma (HCC) downstaging or bridging for liver transplantation (LT) but increase allograft rejection risk. Although immune-related adverse events (irAEs) reflect immune activation during ICI therapy, their association with post-transplant rejection remains unclear. OBJECTIVE: We aimed to identify the risk factors of rejection, focusing on irAEs. DESIGN: This national multicentre retrospective study included 209 adult HCC patients who received pretransplant ICIs from 2018 to 2024. Logistic regression was performed to identify rejection factors and build a predictive model. A prospective observational cohort of 23 HCC patients was enrolled to explore the association between peripheral blood immunophenotype and irAEs. RESULTS: Among 209 patients, 36 (17.2%) experienced rejection with a median time of 10 days post-LT. Multivariate analysis identified irAEs as the strongest predictor of rejection, with an OR of 9.170 (p<0.001). Other independent risk factors were recipient age <40 years (OR=3.028, p=0.049) and washout period <30 days (OR=3.071, p=0.018). The resulting predictive model achieved an area under the curve of 0.788. Moreover, patients with irAEs had significantly increased numbers of peripheral blood CD8+ T cells and higher levels of IFN-α and TNF-α versus those without (all p<0.05). CONCLUSIONS: This study identified irAEs as a potent predictor of allograft rejection in HCC patients receiving pretransplant ICIs, potentially driven by heightened immune activation. The predictive model may help stratify patients at high risk of rejection.
引用
- Fang J, Zhong S, Wang T, et al. Immune-related adverse events are a potent predictor of post-transplant rejection in HCC: a multicentre retrospective cohort study. Gut. 2026. PMID: 41193174. doi:10.1136/gutjnl-2025-336719
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。